V547 Plan: anemia
Written V0547 on the CMS-2567 and in QCOR.
Cited on this tag? What happens after a citation · One-page sheet for the binder
The regulation
§ 494.90(a) Standard: Development of patient plan of care. …The plan of care must address, but not be limited to, the following: (4) Anemia. The interdisciplinary team must provide the necessary care and services to achieve and sustain the clinically appropriate hemoglobin/hematocrit level. The patient’s hemoglobin/hematocrit must be measured at least monthly. The dialysis facility must conduct an evaluation of the patient’s anemia management needs…
CMS's interpretive guidance
Interpretive Guidance § 494.90(a)(4)
The facility must establish targets in anemia management that reflect professionally accepted clinical practice standards.
The IDT should have a plan for managing patients’ anemia. The laboratory reports, orders for erythropoiesis-stimulating agents (ESAs), and medication administration records should be considered as a part of the anemia management program. Facilities that use medication algorithms or protocols for managing anemia must ensure that the care for each patient is individualized. The physician or a non-physician practitioner (i.e., advanced practice registered nurse, or physician assistant) is responsible for ordering medications and laboratory tests and may or may not use standing orders or a standard algorithm.
Each patient’s laboratory values must be monitored, and those outside the target levels must be addressed by adjusting doses and administering ESAs as ordered. Hemoglobin/hematocrit values must be measured at least monthly; many facilities measure these more frequently, especially if the values are outside the recommended target range or the patient has co-morbid conditions (such as cardiovascular disease), which may warrant more frequent monitoring. The IDT team must assess each patient to identify their unique needs for anemia management.
If there is a trend of problems in managing an individual patient’s anemia, the IDT must develop an outcome-oriented plan based on their assessment of the problem and identification of possible barriers to attaining the goals. Due to various co-morbid conditions (e.g., sickle cell disease, persistent iron deficiency, frequent hospitalizations, chronic blood loss, cancer, infection, fluid volume overload), some patients may not respond to ESA therapy as expected. In the event of hyporesponse, there must be evidence that the patient was evaluated for the possible underlying cause(s) of resistance to anemia management therapy, and the plan of care revised accordingly. ESA therapies have been found to be detrimental to some patients when administered at high doses or when the hemoglobin level is driven above 13. The IDT must consider all information regarding ESA therapies when managing the anemia of individual patients.
The requirements for patient assessment of anemia are at V507.
Questions on this site that cite it
Rulebook subjects that cite it
https://middlemolecule.com/rulebook/tags/v547/